“Efficacy and safety of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with active systemic lupus erythematosus: Results from a phase 2, randomized, double-blind, placebo-controlled study” (2023) SKIN The Journal of Cutaneous Medicine, 7(2), p. s114. doi:10.25251/skin.7.supp.114.